

Supplementary material

Table S1. Sources of clinical breakpoints cited in various studies

| | Ceccarelli et al. (2015) | Bier et al. (2015) | Baron et al. (2016) | Baron et al. (2017) | Lepuschitz et al. (2019) |
|-------------------------------|--------------------------|--------------------|---------------------|---------------------|--------------------------|
| Amoxicillin/Clavulanic acid | CLSI (2010a) | CLSI (2010a) | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |
| Amikacin | CLSI (2010a) | | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |
| Ampicillin | CLSI (2010a) | CLSI (2010a) | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |
| Cefepime | CLSI (2010a) | | | | |
| Cefotaxime | CLSI (2010a) | CLSI (2010a) | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |
| Ceftazidime | CLSI (2010a) | CLSI (2010a) | | | |
| Chloramphenicol | CLSI (2010a) | | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |
| Ciprofloxacin | CLSI (2010a) | CLSI (2010a) | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |
| Erythromycin | | | CLSI (2016) | | |
| Florfenicol | | | | | |
| Gentamicin | | CLSI (2015b) | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |
| Imipenem | CLSI (2010a) | CLSI (2015b) | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |
| Meropenem | | CLSI (2015b) | | | |
| Nalidixic acid | CLSI (2010b) | CLSI (2015b) | CLSI (2016) | CLSI (2016) | CLSI (2018) |
| Norfloxacin | | | CLSI (2016) | CLSI (2016) | CLSI (2018) |
| Streptomycin | CLSI (2010b) | | | CLSI (2016) | CLSI (2018) |
| Tetracycline | CLSI (2010a) | CLSI (2010a) | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |
| Trimethoprim | | CLSI (2015b) | | | CLSI (2018) |
| Trimethoprim-sulfamethoxazole | CLSI (2010a) | CLSI (2010a) | CLSI (2010a) | CLSI (2015a) | CLSI (2015a) |

Table S2. Suppliers of discs used by each laboratory. Oxoid discs obtained from Thermo Scientific, Landsmeer, the Netherlands. Mast discs obtained from Mast Group, Bootle, UK. Biorad discs obtained from Bio-Rad, Marnes-la-Coquette, France. AGES: Institute for Medical Microbiology and Hygiene at the Austrian Federal Agency for Health and Food Safety, Vienna, Austria; Anses: The Mycoplasmaology-Bacteriology and Antimicrobial Resistance Unit of Ploufragan-Plouzané-Niort Laboratory of the French Agency for Food, Environmental and Occupational Health & Safety, France; ICC: Inter-University Cooperation Centre Water & Health at Karl Landsteiner University of Health Sciences, Division Water Quality & Health, Krems, Austria; BfR: the Consultant Laboratory for *Vibrio* spp. in food hosted at the German Federal Institute for Risk Assessment, Berlin, Germany.

| | AGES | Anses | BfR | ICC |
|---|-------|--------|-------|-------|
| Amoxicillin/ Clavulanic acid (20/10 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Amikacin (30 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Ampicillin (10 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Cefepime (30 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Chloramphenicol (30 µg) | Oxoid | Mast | Oxoid | Oxoid |
| Ciprofloxacin (5 µg) | Oxoid | Mast | Oxoid | Oxoid |
| Cefotaxime (30 µg) | Oxoid | Mast | Oxoid | Oxoid |
| Ceftazidime (30 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Erythromycin (15 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Florfenicol (30 µg) | Oxoid | Mast | Oxoid | Oxoid |
| Gentamicin (10 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Imipenem (10 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Meropenem (10 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Nalidixic acid (30 µg) | Oxoid | Mast | Oxoid | Oxoid |
| Norfloxacin (10 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Streptomycin (10 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Tetracycline (30 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Trimethoprim (5 µg) | Oxoid | Biorad | Oxoid | Oxoid |
| Trimethoprim-sulfamethoxazole (1.25/23.75 µg) | Oxoid | Oxoid | Oxoid | Oxoid |

Table S3 (individual parts S3.1–S3.19 on subsequent pages). Raw disc zone data for each laboratory (abbreviations as in Table S2) and for multi-laboratory aggregations. Columns shaded in grey indicate zone sizes for isolates that would be categorised as WT by the application of the CO_{WT} calculated from the aggregations or censored aggregations of the data from the participating laboratories. Zone sizes in red indicate data sets from individual laboratories which because of their excessive SD values (>3.39 mm) were excluded from censored aggregations.

Table S3.1. Amoxicillin-clavulanate (20/10 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | 10 | 1 | | | 11 |
| 20 | 9 | 5 | | 1 | 15 |
| 21 | 7 | 19 | 8 | 13 | 47 |
| 22 | 4 | 10 | 23 | 6 | 43 |
| 23 | | 4 | 9 | 5 | 18 |
| 24 | | | 8 | 1 | 9 |
| 25 | | | 1 | 1 | 2 |
| 26 | | | | | 0 |
| 27 | | | | 1 | 1 |
| 28 | | | | 1 | 1 |
| 29 | | | | | |
| 30 | | | | | |
| 31 | | | | | |
| 32 | | | | | |
| 33 | | | | | |
| 34 | | | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 18 | 19 | 19 | 14 | 18 |
| SD | 1.1 | 0.94 | 1.5 | 2.9 | 1.5 |
| <i>E. coli</i> | Acceptable range 17–22 mm | | | | |
| ATCC 35218 | 19 | 21 | 21 | 20 | |

Table S3.2. Amikacin (30 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | 4 | | | | 4 |
| 20 | 15 | | 6 | 6 | 27 |
| 21 | 8 | 9 | 8 | 15 | 40 |
| 22 | 2 | 18 | 26 | 7 | 53 |
| 23 | 1 | 9 | 5 | 1 | 16 |
| 24 | | 3 | 4 | | 7 |
| 25 | | | | | |
| 26 | | | | | |
| 27 | | | | | |
| 28 | | | | | |
| 29 | | | | | |
| 30 | | | | | |
| 31 | | | | | |
| 32 | | | | | |
| 33 | | | | | |
| 34 | | | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 18 | 20 | 18 | 19 | 18 |
| SD | 0.9 | 1.5 | 1.3 | 0.8 | 1.2 |
| <i>E. coli</i> | Acceptable range 19–26 mm | | | | |
| ATCC 25922 | 19 | 21 | 21 | 20 | |

Table S3.3. Ampicillin (10 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | 1 | | 1 |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | 1 | | 1 |
| 10 | | | 1 | | 1 |
| 11 | | | 4 | | 4 |
| 12 | | | | | |
| 13 | | | 1 | | 1 |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | 12 | | | | 12 |
| 20 | 12 | | | 8 | 20 |
| 21 | 4 | 1 | | 12 | 17 |
| 22 | 2 | 4 | 3 | 5 | 14 |
| 23 | | 10 | 9 | | 19 |
| 24 | | 11 | 15 | 2 | 28 |
| 25 | | 7 | 11 | 1 | 19 |
| 26 | | 5 | 1 | 1 | 7 |
| 27 | | 1 | 2 | | 3 |
| 28 | | | | | |
| 29 | | | | | |
| 30 | | | | | |
| 31 | | | | | |
| 32 | | | | | |
| 33 | | | | | |
| 34 | | | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 18 | 20 | 21 | 16 | 19 |
| SD | 1.0 | 1.5 | 1.0 | 2.2 | 1.6 |
| <i>E. coli</i> | Acceptable range 15–22 mm | | | | |
| ATCC 25922 | 17 | 17 | 15 | 18 | |

Table S3.4. Cefepime (30 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | | | | | |
| 26 | | | | | |
| 27 | | 1 | | | 1 |
| 28 | 4 | 1 | 1 | 1 | 7 |
| 29 | 7 | | 1 | | 8 |
| 30 | 4 | 5 | 6 | 6 | 21 |
| 31 | 3 | 6 | 9 | 4 | 22 |
| 32 | 6 | 11 | 11 | 13 | 41 |
| 33 | 5 | 5 | 9 | 5 | 24 |
| 34 | 1 | 6 | 8 | | 15 |
| 35 | | 1 | 2 | | 3 |
| 36 | | 1 | 1 | | 2 |
| 37 | | 2 | | | 2 |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 25 | 26 | 28 | 29 | 28 |
| SD | 2.4 | 2.2 | 1.6 | 0.9 | 1.5 |
| <i>E. coli</i> | Acceptable range 31–37 mm | | | | |
| ATCC 25922 | 32 | 37 | | 33 | |

Table S3.5. Cefotaxime (30 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | | | | | |
| 26 | | | | | |
| 27 | | | | | |
| 28 | | | | | |
| 29 | | | | | |
| 30 | | | | | |
| 31 | | | | 1 | 1 |
| 32 | 1 | | | | 1 |
| 33 | 3 | | | | 3 |
| 34 | 1 | | 2 | 4 | 7 |
| 35 | 5 | | | 2 | 7 |
| 36 | 6 | 3 | 3 | 11 | 23 |
| 37 | 4 | 4 | 4 | 3 | 15 |
| 38 | 6 | 10 | 11 | 6 | 33 |
| 39 | 2 | 7 | 8 | | 17 |
| 40 | 2 | 7 | 11 | 2 | 22 |
| 41 | | 6 | 6 | | 12 |
| 42 | | 2 | 3 | | 5 |
| 43 | | | 1 | | 1 |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 32 | 35 | 34 | 31 | 31 |
| SD | 2.0 | 1.6 | 1.8 | 2.0 | 2.4 |
| <i>E. coli</i> | Acceptable range 29–35 mm | | | | |
| ATCC 25922 | 30 | 35 | 34 | 33 | |

Table S3.6. Ceftazidime (30 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | 2 | | 3 | | 5 |
| 26 | 2 | 1 | 3 | 1 | 7 |
| 27 | 6 | 3 | 8 | 1 | 18 |
| 28 | 4 | 6 | 12 | 3 | 25 |
| 29 | 6 | 17 | 10 | 8 | 41 |
| 30 | 6 | 6 | 7 | 12 | 31 |
| 31 | 1 | 4 | 4 | 1 | 10 |
| 32 | 3 | 1 | 1 | 3 | 8 |
| 33 | | 1 | | | 1 |
| 34 | | | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 23 | 26 | 24 | 25 | 24 |
| SD | 2.2 | 1.4 | 1.7 | 1.6 | 2.3 |
| <i>E. coli</i> | Acceptable range 25–32 mm | | | | |
| ATCC 25922 | 23 | 24 | | 29 | |

Table S3.7. Chloramphenicol (30 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | | | | | |
| 26 | 1 | | | | 1 |
| 27 | 3 | | | | 3 |
| 28 | 3 | 2 | 7 | | 12 |
| 29 | 7 | 8 | 9 | | 24 |
| 30 | 6 | 10 | 3 | 15 | 34 |
| 31 | 4 | 9 | 5 | 7 | 25 |
| 32 | 3 | 7 | 8 | 5 | 23 |
| 33 | 3 | | 3 | 1 | 7 |
| 34 | | 3 | 12 | 1 | 16 |
| 35 | | | 1 | | 1 |
| 36 | | | 1 | | 1 |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 24 | 25 | 30 | 28 | 24 |
| SD | 2.3 | 2.0 | 1.3 | 1.1 | 2.5 |
| <i>E. coli</i> | Acceptable range 21–27 mm | | | | |
| ATCC 2592 | 25 | 22 | 27 | 25 | |

Table S3.8. Ciprofloxacin (5 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | | | | | |
| 26 | | | | | |
| 27 | | | | | |
| 28 | | | | | |
| 29 | | | | | |
| 30 | | | 2 | | 2 |
| 31 | | | 8 | | 8 |
| 32 | 3 | | 7 | 2 | 12 |
| 33 | 2 | | 2 | | 4 |
| 34 | 2 | 4 | 4 | 5 | 15 |
| 35 | 4 | 2 | 8 | 1 | 15 |
| 36 | 6 | 5 | 8 | 14 | 33 |
| 37 | 2 | 9 | 2 | | 13 |
| 38 | 6 | 10 | 4 | 4 | 24 |
| 39 | 2 | 4 | 3 | | 9 |
| 40 | 3 | 4 | 1 | 3 | 11 |
| 41 | | 1 | | | 1 |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 31 | 33 | 27 | 27 | 31 |
| SD | 2.3 | 1.8 | 2.9 | 2.9 | 2.3 |
| <i>E. coli</i> | Acceptable range 29–38 mm | | | | |
| ATCC 2592 | 32 | 35 | 37 | 36 | |

Table S3.9. Erythromycin (15 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|----------|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | 2 | | | 2 |
| 17 | | | | 1 | 1 |
| 18 | | 1 | 10 | | 11 |
| 19 | 8 | 3 | 15 | 4 | 30 |
| 20 | 7 | 6 | 13 | 8 | 34 |
| 21 | 6 | 17 | 6 | 10 | 39 |
| 22 | 3 | 2 | 3 | 5 | 13 |
| 23 | 5 | 5 | 2 | 1 | 13 |
| 24 | | 2 | | | 2 |
| 25 | | 1 | | | 1 |
| 26 | | | | | |
| 27 | 1 | | | | 1 |
| 28 | | | | | |
| 29 | | | | | |
| 30 | | | | | |
| 31 | | | | | |
| 32 | | | | | |
| 33 | | | | | |
| 34 | | | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 14 | 17 | 15 | 18 | 16 |
| SD | 2.4 | 1.9 | 1.6 | 1.1 | 1.7 |
| <i>S. aureus</i> | Acceptable range 22–30 mm | | | | |
| ATCC 25923 | 28 | 27 | 28,30,30 | 29 | |

Table S3.10. Florfenicol

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | | | | | |
| 26 | | | | | |
| 27 | | | | | |
| 28 | 1 | | 1 | | 2 |
| 29 | 2 | 1 | 4 | | 10 |
| 30 | 3 | 7 | 7 | 10 | 27 |
| 31 | 10 | 12 | 15 | 6 | 51 |
| 32 | 6 | 12 | 7 | 12 | 39 |
| 33 | 3 | 5 | 7 | | 20 |
| 34 | 2 | 1 | 6 | 1 | 10 |
| 35 | 2 | | 1 | | 3 |
| 36 | | 1 | | | 2 |
| 37 | | | | | |
| 38 | 1 | | | | 1 |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 25 | 28 | 26 | 26 | 27 |
| SD | 2.4 | 1.2 | 2.1 | 2.1 | 1.6 |
| <i>E. coli</i> | Acceptable range 22–28 mm | | | | |
| ATCC 25922 | 24 | 22 | | 23 | |

Table S3.11. Gentamicin (10 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | 1 | 1 | | 4 | 6 |
| 20 | 8 | 5 | | 18 | 31 |
| 21 | 17 | 9 | | 7 | 33 |
| 22 | 4 | 11 | 3 | | 18 |
| 23 | | 6 | 14 | | 20 |
| 24 | | 3 | 23 | | 26 |
| 25 | | 4 | 7 | | 11 |
| 26 | | | 2 | | 2 |
| 27 | | | | | |
| 28 | | | | | |
| 29 | | | | | |
| 30 | | | | | |
| 31 | | | | | |
| 32 | | | | | |
| 33 | | | | | |
| 34 | | | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 19 | 17 | 21 | 18 | 16 |
| SD | 0.8 | 1.9 | 0.9 | 0.6 | 2.2 |
| <i>E. coli</i> | Acceptable range 19–26 mm | | | | |
| ATCC 25922 | 20 | 24 | 19 | 22 | |

Table S3.12. Imipenem (10 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------------------------|---------------------------|-------|----------|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | 1 | 1 |
| 23 | 2 | | | | 2 |
| 24 | 10 | 1 | 3 | 8 | 22 |
| 25 | 10 | 4 | 12 | 13 | 39 |
| 26 | 5 | 11 | 17 | 3 | 36 |
| 27 | 3 | 16 | 10 | 2 | 31 |
| 28 | | 6 | 5 | | 11 |
| 29 | | | 2 | | 2 |
| 30 | | 1 | | 2 | 3 |
| 31 | | | | | |
| 32 | | | | | |
| 33 | | | | | |
| 34 | | | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 22 | 24 | 23 | 18 | 23 |
| SD | 1.2 | 1.0 | 1.3 | 2.6 | 1.3 |
| <i>P. aeruginosa</i> ATCC 27853 | Acceptable range 20–28 mm | | | | |
| | 23 | 24 | 23,25,28 | 22 | |

Table S3.13. Meropenem (10 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------------------------|---------------------------|-------|----------|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | 1 | | | 1 |
| 25 | 3 | 1 | | | 4 |
| 26 | 8 | 2 | | 1 | 11 |
| 27 | 9 | 13 | 7 | 13 | 42 |
| 28 | 8 | 15 | 38 | 11 | 72 |
| 29 | 2 | 4 | 3 | 3 | 12 |
| 30 | | 2 | 1 | 1 | 4 |
| 31 | | 1 | | | 1 |
| 32 | | | | | |
| 33 | | | | | |
| 34 | | | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| 9CO _{WT} | 24 | 24 | 26 | 26 | 25 |
| SD | 1.1 | 1.3 | 0.9 | 0.9 | 0.8 |
| <i>P. aeruginosa</i> ATCC 27853 | Acceptable range 27–33 mm | | | | |
| | 31 | 29 | 30,32,33 | 33 | |

Table S3.14. Nalidixic acid (30 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | | | | | |
| 26 | | | | | |
| 27 | | | | | |
| 28 | | | 1 | | 1 |
| 29 | | | | | |
| 30 | 2 | 6 | 4 | 1 | 13 |
| 31 | 1 | 3 | 5 | 1 | 10 |
| 32 | 7 | 7 | 13 | 5 | 32 |
| 33 | 8 | 12 | 8 | 3 | 31 |
| 34 | 8 | 8 | 10 | 16 | 42 |
| 35 | 3 | 2 | 5 | 1 | 11 |
| 36 | 1 | 1 | 1 | 2 | 5 |
| 37 | | | 2 | | 2 |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 30 | 26 | 29 | 30 | 29 |
| SD | 1.4 | 1.3 | 1.7 | 1.5 | 1.4 |
| <i>E. coli</i> | Acceptable range 22–28 mm | | | | |
| ATCC 25922 | 28 | 25 | 26 | 28 | |

Table S3.15. Norfloxacin (10 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | | | | | |
| 26 | | | | | |
| 27 | | | | | |
| 28 | | | | | |
| 29 | | | 1 | | 1 |
| 30 | | | 4 | 1 | 5 |
| 31 | 1 | | 4 | | 5 |
| 32 | 3 | | 2 | 17 | 22 |
| 33 | 5 | 1 | 7 | 2 | 15 |
| 34 | 8 | 7 | 10 | 6 | 31 |
| 35 | 7 | 7 | 9 | 1 | 24 |
| 36 | 3 | 7 | 8 | 2 | 20 |
| 37 | 1 | 10 | 1 | | 12 |
| 38 | 2 | 4 | 1 | | 7 |
| 39 | | | 2 | | 2 |
| 40 | | 3 | | | 3 |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 29 | 29 | 30 | 28 | 28 |
| SD | 2.1 | 2.4 | 1.9 | 1.9 | 2.4 |
| <i>E. coli</i> | Acceptable range 28–35 mm | | | | |
| ATCC 25922 | 30 | 35 | 34 | 32 | |

Table S3.16. Streptomycin (10 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | 4 | 5 | 3 | 1 | 13 |
| 14 | 14 | 6 | 15 | 12 | 47 |
| 15 | 7 | 19 | 13 | 11 | 50 |
| 16 | 4 | 5 | 17 | 3 | 29 |
| 17 | 1 | 1 | 1 | 2 | 5 |
| 18 | | 2 | | | 2 |
| 19 | | 1 | | | 1 |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | | | | | |
| 26 | | | | | |
| 27 | | | | | |
| 28 | | | | | |
| 29 | | | | | |
| 30 | | | | | |
| 31 | | | | | |
| 32 | | | | | |
| 33 | | | | | |
| 34 | | | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 11 | 9 | 11 | 13 | 13 |
| SD | 1.2 | 1.9 | 1.5 | 1.0 | 1.0 |
| <i>E. coli</i> | Acceptable range 12–20 mm | | | | |
| ATCC 25922 | 16 | 17 | 19 | 18 | |

Table S3.17. Tetracycline (30 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Aggregation |
|------------------|---------------------------|-------|-----|-----|-------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | 1 | 2 | 3 |
| 25 | 1 | | 1 | 4 | 6 |
| 26 | 2 | | 6 | 8 | 16 |
| 27 | 9 | 7 | 6 | 7 | 29 |
| 28 | 9 | 8 | 9 | 8 | 34 |
| 29 | 8 | 8 | 7 | | 23 |
| 30 | 1 | 11 | 9 | | 21 |
| 31 | | 1 | 7 | | 8 |
| 32 | | 4 | 2 | | 6 |
| 33 | | | | | |
| 34 | | | | | |
| 35 | | | 1 | | 1 |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 25 | 23 | 25 | 22 | 23 |
| SD | 1.2 | 2.0 | 1.8 | 1.6 | 1.9 |
| <i>E. coli</i> | Acceptable range 18–25 mm | | | | |
| ATCC 25922 | 23 | 23 | 22 | 23 | |

Table S3.18. Trimethoprim (5 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Censored aggregation |
|------------------|---------------------------|-------|-----|-----|----------------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | 1 | | | | 1 |
| 23 | | 4 | | | |
| 24 | 4 | 5 | | 1 | 5 |
| 25 | 6 | 9 | 8 | 3 | 17 |
| 26 | 11 | 4 | 39 | 9 | 59 |
| 27 | 5 | 7 | 2 | 9 | 16 |
| 28 | 2 | 1 | | 5 | 7 |
| 29 | 1 | 3 | | 1 | 2 |
| 30 | | 2 | | 1 | 1 |
| 31 | | 1 | | | |
| 32 | | 1 | | | |
| 33 | | 1 | | | |
| 34 | | 1 | | | |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 23 | 15 | 25 | 23 | 23 |
| SD | 1.1 | 4.1 | 1.8 | 1.3 | 1.3 |
| <i>E. coli</i> | Acceptable range 21–28 mm | | | | |
| ATCC 25922 | 26 | 23 | 24 | 23 | |

As its SD was excessive, the data from Anses was not included in the censored aggregation

Table S3.19. Trimethoprim-sulfamethoxazole (1.25/23.75 µg)

| Zones (mm) | AGES | Anses | BfR | ICC | Censored aggregation |
|------------------|---------------------------|-------|-----|-----|----------------------|
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |
| 11 | | | | | |
| 12 | | | | | |
| 13 | | | | | |
| 14 | | | | | |
| 15 | | | | | |
| 16 | | | | | |
| 17 | | | | | |
| 18 | | | | | |
| 19 | | | | | |
| 20 | | | | | |
| 21 | | | | | |
| 22 | | | | | |
| 23 | | | | | |
| 24 | | | | | |
| 25 | | 1 | 4 | | 5 |
| 26 | 4 | 4 | 1 | | 9 |
| 27 | 8 | 9 | 7 | 4 | 24 |
| 28 | 13 | 5 | 12 | 4 | 30 |
| 29 | 5 | 5 | 8 | 4 | 18 |
| 30 | | 10 | 8 | 15 | 18 |
| 31 | | 4 | 4 | 1 | 8 |
| 32 | | 1 | 2 | 1 | 3 |
| 33 | | | 2 | | 2 |
| 34 | | | 1 | | 1 |
| 35 | | | | | |
| 36 | | | | | |
| 37 | | | | | |
| 38 | | | | | |
| 39 | | | | | |
| 40 | | | | | |
| 41 | | | | | |
| 42 | | | | | |
| 43 | | | | | |
| 44 | | | | | |
| 45 | | | | | |
| 46 | | | | | |
| 47 | | | | | |
| 48 | | | | | |
| 49 | | | | | |
| 50 | | | | | |
| CO _{WT} | 25 | 24 | 23 | 18 | 24 |
| SD | 0.9 | 1.7 | 2.3 | 4.1 | 1.9 |
| <i>E. coli</i> | Acceptable range 23–29 mm | | | | |
| ATCC 25922 | 26 | 26 | 27 | 28 | |

As its SD was excessive, the data from ICC was not included in the censored aggregation

LITERATURE CITED

- Baron S, Lesne J, Jouy E, Larvor E and others (2016) Antimicrobial susceptibility of autochthonous aquatic *Vibrio cholerae* in Haiti. *Front Microbiol* 7:1671
- Baron S, Larvor E, Chevalier S, Jouy E, Kempf I, Granier SA, Lesne J (2017) Antimicrobial susceptibility among urban wastewater and wild shellfish isolates of non-O1/non-O139 *Vibrio cholerae* from La Rance Estuary (Brittany, France). *Front Microbiol* 8:1637
- Bier N, Schwartz K, Guerra B, Strauch E (2015) Survey on antimicrobial resistance patterns in *Vibrio vulnificus* and *Vibrio cholerae* non-O1/non-O139 in Germany reveals carbapenemase-producing *Vibrio cholerae* in coastal waters. *Front Microbiol* 6:1179
- Ceccarelli D, Chen A, Hasan NA, Rashed SM, Huq A, Colwell RR (2015) Non-O1/non-O139 *Vibrio cholerae* carrying multiple virulence factors and *V. cholerae* O1 in the Chesapeake Bay, Maryland. *Appl Environ Microbiol* 81:1909–1918
- CLSI (2010a) Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, CLSI guideline M45, 2nd edn. Clinical and Laboratory Standards Institute, Wayne, PA
- CLSI (2010b) Performance standards for antimicrobial susceptibility testing, twentieth informational supplement. M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA
- CLSI (2015a) Methods for antimicrobial dilution and disc susceptibility testing of infrequently isolated or fastidious bacteria. CLSI guideline M45, 3rd edn. Clinical and Laboratory Standards Institute, Wayne, PA
- CLSI (2015b) Performance standards for antimicrobial susceptibility testing, twenty-fifth informational supplement M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA
- CLSI (2016) Performance standards for antimicrobial susceptibility testing, twenty-sixth informational supplement M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA
- CLSI (2018) Performance standards for antimicrobial susceptibility testing, twenty-eighth informational supplement M100-S28. Clinical and Laboratory Standards Institute, Wayne, PA
- Lepuschitz S, Baron S, Larvor E, Granier SA and others (2019) Phenotypic and genotypic antimicrobial resistance traits of *Vibrio cholerae* non-O1/non-O139 isolated from a large Austrian lake frequently associated with cases of human infection. *Front Microbiol* 10:2600